Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Washington